REGENERX BIOPHARMACEUTICALS INC has a total of 34 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2001. It filed its patents most often in Australia, United States and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are GEFFARD MICHEL, CONARIS RES INSTITUTE AG and LA JOLLA PHARMA CO.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 18 | |
#2 | United States | 5 | |
#3 | Canada | 3 | |
#4 | Hong Kong | 3 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | China | 1 | |
#7 | Mexico | 1 | |
#8 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Organic fine chemistry | |
#6 | Environmental technology | |
#7 | Machines |
# | Name | Total Patents |
---|---|---|
#1 | Goldstein Allan L | 29 |
#2 | Crockford David | 11 |
#3 | Finkelstein Jack Jr | 6 |
#4 | Sosne Gabriel | 5 |
#5 | David Crockford | 3 |
#6 | Hannappel Ewald | 2 |
#7 | Allan Christian B | 2 |
#8 | Finkelstein J J | 2 |
#9 | Gabriel Sosne | 1 |
#10 | Allan L Goldstein L | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020231989A1 | Compositions and methods for treatment of chronic granulomatous disease | |
AU2007207609A1 | Methods of treating or preventing tissue damage caused by increased blood flow | |
AU2006233251A1 | Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives | |
AU2005222085A2 | Treating or preventing extracellular matrix build-up | |
AU2002213513B2 | Inhibition or reversal of skin aging by actin-sequestering peptides |